Efficacy of an orlistat‐resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial

Objective To evaluate the efficacy of an orlistat‐resveratrol (O‐R) combination in subjects with obesity over a 6‐month period. Methods This study was a double‐blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection criteria (age from 20 to 60 years and body mass ind...

Full description

Saved in:
Bibliographic Details
Published inObesity (Silver Spring, Md.) Vol. 24; no. 7; pp. 1454 - 1463
Main Authors Arzola‐Paniagua, María Angélica, García‐Salgado López, Enrique Raúl, Calvo‐Vargas, Cesar G., Guevara‐Cruz, Martha
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.07.2016
Subjects
Online AccessGet full text
ISSN1930-7381
1930-739X
1930-739X
DOI10.1002/oby.21523

Cover

Abstract Objective To evaluate the efficacy of an orlistat‐resveratrol (O‐R) combination in subjects with obesity over a 6‐month period. Methods This study was a double‐blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection criteria (age from 20 to 60 years and body mass index (BMI) ≥30 and ≤39.9 kg/m2) consumed an energy‐reduced diet with 500 fewer calories than their usual diet for 2 weeks. Then the participants were randomly assigned to four groups, placebo, resveratrol, orlistat, or O‐R, and they consumed the energy‐reduced diet for 6 months. The study consisted of seven visits. During each visit, a 24‐h recall was performed, along with measurements of anthropometric and serum biochemical parameters. Results A total of 161 participants were selected. Of these, 84 participants completed the study. A significant weight loss of −6.82 kg (95% CI −8.37 to −5.26) was observed in the O‐R group compared with −3.50 kg (−5.05 to −1.95, P = 0.021) in the placebo group. In contrast, the −6.02 kg (−7.68 to −4.36) orlistat and −4.68 kg (−6.64 to −2.71) resveratrol monotherapy losses did not significantly differ from the placebo. Significant decreases in BMI, waist circumference, fat mass, triglycerides, leptin, and leptin/adiponectin ratio were observed with the O‐R combination. Conclusions The O‐R combination was the most effective weight loss treatment.
AbstractList To evaluate the efficacy of an orlistat-resveratrol (O-R) combination in subjects with obesity over a 6-month period.OBJECTIVETo evaluate the efficacy of an orlistat-resveratrol (O-R) combination in subjects with obesity over a 6-month period.This study was a double-blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection criteria (age from 20 to 60 years and body mass index (BMI) ≥30 and ≤39.9 kg/m(2) ) consumed an energy-reduced diet with 500 fewer calories than their usual diet for 2 weeks. Then the participants were randomly assigned to four groups, placebo, resveratrol, orlistat, or O-R, and they consumed the energy-reduced diet for 6 months. The study consisted of seven visits. During each visit, a 24-h recall was performed, along with measurements of anthropometric and serum biochemical parameters.METHODSThis study was a double-blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection criteria (age from 20 to 60 years and body mass index (BMI) ≥30 and ≤39.9 kg/m(2) ) consumed an energy-reduced diet with 500 fewer calories than their usual diet for 2 weeks. Then the participants were randomly assigned to four groups, placebo, resveratrol, orlistat, or O-R, and they consumed the energy-reduced diet for 6 months. The study consisted of seven visits. During each visit, a 24-h recall was performed, along with measurements of anthropometric and serum biochemical parameters.A total of 161 participants were selected. Of these, 84 participants completed the study. A significant weight loss of -6.82 kg (95% CI -8.37 to -5.26) was observed in the O-R group compared with -3.50 kg (-5.05 to -1.95, P = 0.021) in the placebo group. In contrast, the -6.02 kg (-7.68 to -4.36) orlistat and -4.68 kg (-6.64 to -2.71) resveratrol monotherapy losses did not significantly differ from the placebo. Significant decreases in BMI, waist circumference, fat mass, triglycerides, leptin, and leptin/adiponectin ratio were observed with the O-R combination.RESULTSA total of 161 participants were selected. Of these, 84 participants completed the study. A significant weight loss of -6.82 kg (95% CI -8.37 to -5.26) was observed in the O-R group compared with -3.50 kg (-5.05 to -1.95, P = 0.021) in the placebo group. In contrast, the -6.02 kg (-7.68 to -4.36) orlistat and -4.68 kg (-6.64 to -2.71) resveratrol monotherapy losses did not significantly differ from the placebo. Significant decreases in BMI, waist circumference, fat mass, triglycerides, leptin, and leptin/adiponectin ratio were observed with the O-R combination.The O-R combination was the most effective weight loss treatment.CONCLUSIONSThe O-R combination was the most effective weight loss treatment.
Objective To evaluate the efficacy of an orlistat‐resveratrol (O‐R) combination in subjects with obesity over a 6‐month period. Methods This study was a double‐blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection criteria (age from 20 to 60 years and body mass index (BMI) ≥30 and ≤39.9 kg/m2) consumed an energy‐reduced diet with 500 fewer calories than their usual diet for 2 weeks. Then the participants were randomly assigned to four groups, placebo, resveratrol, orlistat, or O‐R, and they consumed the energy‐reduced diet for 6 months. The study consisted of seven visits. During each visit, a 24‐h recall was performed, along with measurements of anthropometric and serum biochemical parameters. Results A total of 161 participants were selected. Of these, 84 participants completed the study. A significant weight loss of −6.82 kg (95% CI −8.37 to −5.26) was observed in the O‐R group compared with −3.50 kg (−5.05 to −1.95, P = 0.021) in the placebo group. In contrast, the −6.02 kg (−7.68 to −4.36) orlistat and −4.68 kg (−6.64 to −2.71) resveratrol monotherapy losses did not significantly differ from the placebo. Significant decreases in BMI, waist circumference, fat mass, triglycerides, leptin, and leptin/adiponectin ratio were observed with the O‐R combination. Conclusions The O‐R combination was the most effective weight loss treatment.
To evaluate the efficacy of an orlistat-resveratrol (O-R) combination in subjects with obesity over a 6-month period. This study was a double-blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection criteria (age from 20 to 60 years and body mass index (BMI) ≥30 and ≤39.9 kg/m(2) ) consumed an energy-reduced diet with 500 fewer calories than their usual diet for 2 weeks. Then the participants were randomly assigned to four groups, placebo, resveratrol, orlistat, or O-R, and they consumed the energy-reduced diet for 6 months. The study consisted of seven visits. During each visit, a 24-h recall was performed, along with measurements of anthropometric and serum biochemical parameters. A total of 161 participants were selected. Of these, 84 participants completed the study. A significant weight loss of -6.82 kg (95% CI -8.37 to -5.26) was observed in the O-R group compared with -3.50 kg (-5.05 to -1.95, P = 0.021) in the placebo group. In contrast, the -6.02 kg (-7.68 to -4.36) orlistat and -4.68 kg (-6.64 to -2.71) resveratrol monotherapy losses did not significantly differ from the placebo. Significant decreases in BMI, waist circumference, fat mass, triglycerides, leptin, and leptin/adiponectin ratio were observed with the O-R combination. The O-R combination was the most effective weight loss treatment.
To evaluate the efficacy of an orlistat-resveratrol (O-R) combination in subjects with obesity over a 6-month period. This study was a double-blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection criteria (age from 20 to 60 years and body mass index (BMI) ≥30 and ≤39.9 kg/m^sup 2^) consumed an energy-reduced diet with 500 fewer calories than their usual diet for 2 weeks. Then the participants were randomly assigned to four groups, placebo, resveratrol, orlistat, or O-R, and they consumed the energy-reduced diet for 6 months. The study consisted of seven visits. During each visit, a 24-h recall was performed, along with measurements of anthropometric and serum biochemical parameters. A total of 161 participants were selected. Of these, 84 participants completed the study. A significant weight loss of -6.82 kg (95% CI -8.37 to -5.26) was observed in the O-R group compared with -3.50 kg (-5.05 to -1.95, P = 0.021) in the placebo group. In contrast, the -6.02 kg (-7.68 to -4.36) orlistat and -4.68 kg (-6.64 to -2.71) resveratrol monotherapy losses did not significantly differ from the placebo. Significant decreases in BMI, waist circumference, fat mass, triglycerides, leptin, and leptin/adiponectin ratio were observed with the O-R combination. The O-R combination was the most effective weight loss treatment.
Author García‐Salgado López, Enrique Raúl
Arzola‐Paniagua, María Angélica
Calvo‐Vargas, Cesar G.
Guevara‐Cruz, Martha
Author_xml – sequence: 1
  givenname: María Angélica
  surname: Arzola‐Paniagua
  fullname: Arzola‐Paniagua, María Angélica
  organization: Instituto Biosen A.C
– sequence: 2
  givenname: Enrique Raúl
  surname: García‐Salgado López
  fullname: García‐Salgado López, Enrique Raúl
  organization: Instituto Biosen A.C
– sequence: 3
  givenname: Cesar G.
  surname: Calvo‐Vargas
  fullname: Calvo‐Vargas, Cesar G.
  organization: Centro de Diseño y Planeación en Investigación Médica S.C
– sequence: 4
  givenname: Martha
  surname: Guevara‐Cruz
  fullname: Guevara‐Cruz, Martha
  organization: Instituto Nacional de Ciencias Médicas y Nutrición
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27221771$$D View this record in MEDLINE/PubMed
BookMark eNp9kcFO3DAURa0KVGDaRX-gstQNLAae7SRO2AGigITEppXaVeQ4dvHIscF2GIUVn8A39kvwMMACqV29tzj3vqd7d9CG804h9IXAPgGgB76b9ikpKfuAtknDYM5Z82vjba_JFtqJcQFQVFCSj2iLckoJ52QbTadaGynkhL3GwmEfrIlJpL8Pj0HFOxVECt5i6YfOOJGMd1j7gJfK_LlO2PoYsXE4jt1CyRTx0qRr7DsVTZoO8REOwvV-MPeqzxZuZWXzmoIR9hPa1MJG9fllztDP76c_Ts7nl1dnFydHl3NZlDWb94wKEFQwqLpKlaQuagacS1o1FaiyKbqq5h2RFVFallJTXWvZs7IhQvcCgM3Q7tr3JvjbUcXUDiZKZa1wyo-xJTUAoQ3kYzP07R268GNw-bsVxYuaU15m6usLNXaD6tubYAYRpvY11AzsrQEZcj5B6TeEQLsqrM2Ftc-FZfbgHStNes45BWHs_xRLY9X0b-v26vj3WvEEBUGolw
CitedBy_id crossref_primary_10_2174_1573399815666191113125247
crossref_primary_10_1016_j_endmts_2025_100218
crossref_primary_10_1016_j_jff_2019_103646
crossref_primary_10_3389_fendo_2019_00413
crossref_primary_10_3390_nu14102053
crossref_primary_10_1016_j_jep_2023_116789
crossref_primary_10_3390_nu14071424
crossref_primary_10_1186_s13765_022_00712_y
crossref_primary_10_1016_j_clnesp_2020_11_025
crossref_primary_10_1016_j_clnu_2020_01_002
crossref_primary_10_3390_endocrines3020023
crossref_primary_10_1080_10408398_2018_1529654
crossref_primary_10_2174_0929867330666230517124033
crossref_primary_10_3390_ijms21165642
crossref_primary_10_3390_life13010108
crossref_primary_10_1080_07357907_2022_2115057
crossref_primary_10_3390_ijms22095047
crossref_primary_10_1002_14651858_CD015861
crossref_primary_10_1186_s12944_020_1198_x
crossref_primary_10_1016_j_mvr_2020_104054
crossref_primary_10_1038_s41366_021_00921_3
crossref_primary_10_1016_j_molmet_2024_102002
crossref_primary_10_1111_obr_12775
crossref_primary_10_1016_j_lfs_2020_117962
crossref_primary_10_1016_j_phrs_2017_01_012
crossref_primary_10_3390_ijms25020747
crossref_primary_10_3390_ijms23074027
crossref_primary_10_1089_met_2022_0052
crossref_primary_10_1002_med_21565
crossref_primary_10_1016_j_phyplu_2024_100526
crossref_primary_10_1002_lipd_12196
crossref_primary_10_1039_C9FO00293F
crossref_primary_10_1007_s10555_022_10056_0
crossref_primary_10_1080_10408398_2022_2159921
crossref_primary_10_1007_s11154_019_09494_z
crossref_primary_10_3389_fphys_2022_795980
crossref_primary_10_3389_fnut_2023_1140019
crossref_primary_10_3390_nu13020672
crossref_primary_10_1177_1973798X241289779
crossref_primary_10_3390_nu10111651
crossref_primary_10_1007_s13105_018_0648_7
crossref_primary_10_1080_10408398_2021_1875980
crossref_primary_10_1186_s12944_024_02214_w
crossref_primary_10_1016_j_biopha_2021_111282
crossref_primary_10_1002_ptr_8319
crossref_primary_10_1016_j_phrs_2017_12_033
crossref_primary_10_1080_07388551_2024_2424362
Cites_doi 10.1007/s00018-014-1808-8
10.1155/2011/285618
10.1007/s12079-014-0257-3
10.1016/j.bbadis.2014.11.012
10.1038/oby.2004.282
10.1016/j.bcp.2008.11.027
10.1002/oby.20030
10.1073/pnas.0610068104
10.1016/j.phrs.2013.03.011
10.1016/j.ejcb.2008.08.003
10.1016/j.jnutbio.2013.09.001
10.3389/fphar.2015.00079
10.1038/sj.ijo.0803606
10.1016/j.cmet.2011.10.002
10.1038/ijo.2015.23
10.1016/j.numecd.2010.03.003
10.1139/apnm-2015-0075
10.1016/j.biochi.2012.01.008
10.1016/S0024-3205(99)00410-5
10.1002/oby.20263
10.1111/obr.12318
10.1161/circ.106.25.3143
10.1093/ajcn/55.1.309s
10.2337/diacare.27.10.2488
10.1002/oby.20394
10.1111/j.1365-2796.2006.01702.x
10.1097/01.crd.0000380842.14048.7e
10.1016/j.cell.2012.01.017
10.1016/j.atherosclerosis.2009.08.020
10.3389/fphar.2015.00199
10.1017/S0007114511002753
10.1155/2013/136584
10.1016/j.phrs.2011.07.004
10.1016/j.ejim.2012.06.013
ContentType Journal Article
Copyright 2016 The Obesity Society
2016 The Obesity Society.
Copyright Blackwell Publishing Ltd. Jul 2016
Copyright_xml – notice: 2016 The Obesity Society
– notice: 2016 The Obesity Society.
– notice: Copyright Blackwell Publishing Ltd. Jul 2016
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
K9.
7X8
DOI 10.1002/oby.21523
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
ProQuest Health & Medical Complete (Alumni)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1930-739X
EndPage 1463
ExternalDocumentID 4131614221
27221771
10_1002_oby_21523
OBY21523
Genre article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
Feature
GrantInformation_xml – fundername: Laboratorios Senosiain
GroupedDBID ---
05W
0R~
123
1OC
24P
29N
2FS
2WC
31~
33P
39C
3SF
3V.
4.4
50Y
52U
52V
53G
70F
7X7
8-1
8C1
A00
AAESR
AAEVG
AAFWJ
AAHBH
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AASGY
AAWTL
AAXRX
AAYCA
AAZKR
ABCUV
ABIVO
ABJNI
ABLJU
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFKRA
AFPWT
AFWVQ
AFZJQ
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZQEC
AZVAB
BAWUL
BENPR
BFHJK
BHBCM
BKNYI
BMXJE
BOGZA
BPHCQ
BRXPI
BVXVI
CS3
DCZOG
DIK
DPXWK
DRFUL
DRMAN
DRSTM
DU5
E3Z
EBS
EJD
EMOBN
F5P
FUBAC
FYUFA
G-S
GODZA
HGLYW
HZ~
KBYEO
LATKE
LEEKS
LH4
LITHE
LOXES
LUTES
LW6
LYRES
M0R
M1P
MEWTI
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
MY~
O66
O9-
OK1
P2W
PQQKQ
PROAC
PSQYO
R.K
ROL
SUPJJ
UKHRP
WBKPD
WHG
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOQ
WQJ
WVDHM
WXSBR
WYJ
YHZ
AAYXX
AEYWJ
AGHNM
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
K9.
7X8
ID FETCH-LOGICAL-c4583-d32a0a2a306b6e518483077c26960e594b687b1c61efc5cf2f8fcd3591afda003
ISSN 1930-7381
1930-739X
IngestDate Fri Sep 05 11:32:42 EDT 2025
Fri Jul 25 23:52:08 EDT 2025
Mon Jul 21 05:59:47 EDT 2025
Thu Apr 24 22:55:34 EDT 2025
Tue Jul 01 01:16:19 EDT 2025
Wed Jan 22 16:49:10 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
License 2016 The Obesity Society.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c4583-d32a0a2a306b6e518483077c26960e594b687b1c61efc5cf2f8fcd3591afda003
Notes National Clinical Trial Registry (Registro Nacional de Ensayos Clinicos—RNEC) of Mexico identifier 133300410A0152 (ECORL/RES‐052013)
Clinical trial registration
The authors declared no conflict of interest.
Disclosure
Funding agencies
Laboratorios Senosiain S.A. de C.V.
MAAP: protocol development, surveillance of the study follow‐up, manuscript writing, manuscript review; ERGSL: protocol development, manuscript writing, manuscript review; CGCV: patient selection, treatment follow‐up, surveillance of the dietary and pharmacological treatment, data collection; MGC: protocol development, statistical analysis, writing and editing/review of the manuscript.
Author contributions
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/oby.21523
PMID 27221771
PQID 1807487275
PQPubID 105348
PageCount 10
ParticipantIDs proquest_miscellaneous_1800129058
proquest_journals_1807487275
pubmed_primary_27221771
crossref_primary_10_1002_oby_21523
crossref_citationtrail_10_1002_oby_21523
wiley_primary_10_1002_oby_21523_OBY21523
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate July 2016
PublicationDateYYYYMMDD 2016-07-01
PublicationDate_xml – month: 07
  year: 2016
  text: July 2016
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Silver Spring
PublicationTitle Obesity (Silver Spring, Md.)
PublicationTitleAlternate Obesity (Silver Spring)
PublicationYear 2016
Publisher Blackwell Publishing Ltd
Publisher_xml – name: Blackwell Publishing Ltd
References 2007; 104
2009; 88
2015; 39
2015; 6
2015; 16
2010; 209
2013; 21
2004; 27
2015; 72
2000; 66
2014; 25
2015; 1852
2011; 14
2007; 31
2012; 148
1992; 55
2012; 107
2012; 94
2009; 77
2011; 2011
39
2013; 2013
2015; 40
2013; 72
2004; 12
2011; 64
2002; 106
2011; 21
2014
2006; 260
2014; 8
2012; 23
2005; 13
1988
21
e_1_2_6_32_1
e_1_2_6_10_1
e_1_2_6_31_1
e_1_2_6_30_1
Lohman TG (e_1_2_6_25_1) 1988
e_1_2_6_19_1
Bray GA. (e_1_2_6_38_1); 21
e_1_2_6_13_1
e_1_2_6_36_1
e_1_2_6_14_1
e_1_2_6_35_1
e_1_2_6_11_1
e_1_2_6_34_1
e_1_2_6_12_1
e_1_2_6_33_1
e_1_2_6_18_1
e_1_2_6_15_1
e_1_2_6_16_1
e_1_2_6_37_1
e_1_2_6_21_1
e_1_2_6_20_1
Wicklow B (e_1_2_6_17_1) 2014
Grundy SM (e_1_2_6_24_1) 2005; 13
e_1_2_6_9_1
e_1_2_6_8_1
Lau DC (e_1_2_6_29_1); 39
e_1_2_6_5_1
e_1_2_6_4_1
e_1_2_6_7_1
e_1_2_6_6_1
e_1_2_6_3_1
e_1_2_6_23_1
e_1_2_6_2_1
e_1_2_6_22_1
e_1_2_6_28_1
e_1_2_6_27_1
e_1_2_6_26_1
References_xml – volume: 12
  start-page: 151S
  issue: Suppl
  year: 2004
  end-page: 162S
  article-title: Efficacy of lifestyle modification for long‐term weight control
  publication-title: Obes Res
– volume: 55
  start-page: 309S
  year: 1992
  end-page: 313S
  article-title: Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18‐0647 (tetrahydrolipstatin)
  publication-title: Am J Clin Nutr
– volume: 106
  start-page: 3143
  year: 2002
  end-page: 3421
  article-title: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
  publication-title: Circulation
– volume: 8
  start-page: 385
  year: 2014
  end-page: 391
  article-title: Dose response biology of resveratrol in obesity
  publication-title: J Cell Commun Signal
– volume: 13
  start-page: 322
  year: 2005
  end-page: 327
  article-title: Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary
  publication-title: Cardiol Rev
– volume: 39
  start-page: 967
  year: 2015
  end-page: 976
  article-title: Resveratrol induces brown‐like adipocyte formation in white fat through activation of AMP‐activated protein kinase (AMPK) alpha1
  publication-title: Int J Obes (Lond)
– volume: 64
  start-page: 438
  year: 2011
  end-page: 455
  article-title: Dietary phytochemicals and their potential effects on obesity: a review
  publication-title: Pharmacol Res
– volume: 31
  start-page: 1442
  year: 2007
  end-page: 1448
  article-title: Impact of weight loss on the metabolic syndrome
  publication-title: Int J Obes (Lond)
– volume: 16
  start-page: 1071
  year: 2015
  end-page: 1080
  article-title: Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta‐analysis of randomized controlled trials
  publication-title: Obes Rev
– volume: 21
  start-page: 893
  end-page: 899
  article-title: Why do we need drugs to treat the patient with obesity?
  publication-title: Obesity (Silver Spring)
– volume: 72
  start-page: 1473
  year: 2015
  end-page: 1488
  article-title: Metabolic effects of resveratrol: addressing the controversies
  publication-title: Cell Mol Life Sci
– volume: 14
  start-page: 612
  year: 2011
  end-page: 622
  article-title: Calorie restriction‐like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans
  publication-title: Cell Metab
– volume: 148
  start-page: 421
  year: 2012
  end-page: 433
  article-title: Resveratrol ameliorates aging‐related metabolic phenotypes by inhibiting cAMP phosphodiesterases
  publication-title: Cell
– volume: 209
  start-page: 220
  year: 2010
  end-page: 225
  article-title: Leptin, adiponectin, their ratio and risk of coronary heart disease: results from the MONICA/KORA Augsburg Study 1984‐2002
  publication-title: Atherosclerosis
– volume: 2011
  start-page: 285618
  year: 2011
  article-title: Effect of plant polyphenols on adipokine secretion from human SGBS adipocytes
  publication-title: Biochem Res Int
– volume: 6
  start-page: 79
  year: 2015
  article-title: Obesity and inflammation: reduced cytokine expression due to resveratrol in a human in vitro model of inflamed adipose tissue
  publication-title: Front Pharmacol
– volume: 2013
  start-page: 136584
  year: 2013
  article-title: Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome
  publication-title: Mediat Inflamm
– volume: 260
  start-page: 388
  year: 2006
  end-page: 398
  article-title: Evaluation of a primary care‐oriented brief counselling intervention for obesity with and without orlistat
  publication-title: J Intern Med
– volume: 21
  start-page: E154
  year: 2013
  end-page: E161
  article-title: Obesity and body fat classification in the metabolic syndrome: impact on cardiometabolic risk metabotype
  publication-title: Obesity (Silver Spring)
– volume: 21
  start-page: E182
  year: 2013
  end-page: E189
  article-title: Visceral fat resection in humans: effect on insulin sensitivity, beta‐cell function, adipokines, and inflammatory markers
  publication-title: Obesity (Silver Spring)
– volume: 27
  start-page: 2488
  year: 2004
  end-page: 2490
  article-title: Leptin‐to‐adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients
  publication-title: Diabetes Care
– volume: 72
  start-page: 69
  year: 2013
  end-page: 82
  article-title: One‐year supplementation with a grape extract containing resveratrol modulates inflammatory‐related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease
  publication-title: Pharmacol Res
– year: 1988
– volume: 104
  start-page: 7217
  year: 2007
  end-page: 7222
  article-title: Resveratrol stimulates AMP kinase activity in neurons
  publication-title: Proc Natl Acad Sci USA
– start-page: 1
  year: 2014
  end-page: 9
  article-title: Proposed trial: safety and efficacy of resveratrol for the treatment of non‐alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents ‐ rationale and protocol
  publication-title: Biochem Cell Biol
– volume: 39
  start-page: S134
  issue: Suppl 5
  end-page: S141
  article-title: Current and emerging pharmacotherapies for weight management in prediabetes and diabetes
  publication-title: Can J Diabetes
– volume: 40
  start-page: 1129
  year: 2015
  end-page: 1136
  article-title: Resveratrol prevents insulin resistance caused by short‐term elevation of free fatty acids in vivo
  publication-title: Appl Physiol Nutr Metab
– volume: 66
  start-page: 663
  year: 2000
  end-page: 673
  article-title: Biological effects of resveratrol
  publication-title: Life Sci
– volume: 107
  start-page: 202
  year: 2012
  end-page: 210
  article-title: Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress
  publication-title: Br J Nutr
– volume: 94
  start-page: 2126
  year: 2012
  end-page: 2130
  article-title: Up‐ and down‐regulation of adiponectin expression and multimerization: mechanisms and therapeutic implication
  publication-title: Biochimie
– volume: 25
  start-page: 1
  year: 2014
  end-page: 18
  article-title: Novel insights of dietary polyphenols and obesity
  publication-title: J Nutr Biochem
– volume: 23
  start-page: 755
  year: 2012
  end-page: 759
  article-title: The plasma leptin/adiponectin ratio predicts first cardiovascular event in men: a prospective nested case‐control study
  publication-title: Eur J Intern Med
– volume: 21
  start-page: 851
  year: 2011
  end-page: 856
  article-title: Acute resveratrol supplementation improves flow‐mediated dilatation in overweight/obese individuals with mildly elevated blood pressure
  publication-title: Nutr Metab Cardiovasc Dis
– volume: 1852
  start-page: 1137
  year: 2015
  end-page: 1144
  article-title: Resveratrol and obesity: can resveratrol relieve metabolic disturbances?
  publication-title: Biochim Biophys Acta
– volume: 77
  start-page: 1053
  year: 2009
  end-page: 1063
  article-title: Long‐term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats
  publication-title: Biochem Pharmacol
– volume: 88
  start-page: 35
  year: 2009
  end-page: 44
  article-title: Sirt1 increases skeletal muscle precursor cell proliferation
  publication-title: Eur J Cell Biol
– volume: 6
  start-page: 199
  year: 2015
  article-title: Systems pharmacology of adiposity reveals inhibition of EP300 as a common therapeutic mechanism of caloric restriction and resveratrol for obesity
  publication-title: Front Pharmacol
– ident: e_1_2_6_8_1
  doi: 10.1007/s00018-014-1808-8
– ident: e_1_2_6_14_1
  doi: 10.1155/2011/285618
– ident: e_1_2_6_19_1
  doi: 10.1007/s12079-014-0257-3
– ident: e_1_2_6_21_1
  doi: 10.1016/j.bbadis.2014.11.012
– ident: e_1_2_6_37_1
  doi: 10.1038/oby.2004.282
– ident: e_1_2_6_11_1
  doi: 10.1016/j.bcp.2008.11.027
– ident: e_1_2_6_32_1
  doi: 10.1002/oby.20030
– ident: e_1_2_6_7_1
  doi: 10.1073/pnas.0610068104
– ident: e_1_2_6_16_1
  doi: 10.1016/j.phrs.2013.03.011
– volume: 39
  start-page: S134
  issue: 5
  ident: e_1_2_6_29_1
  article-title: Current and emerging pharmacotherapies for weight management in prediabetes and diabetes
  publication-title: Can J Diabetes
– ident: e_1_2_6_36_1
  doi: 10.1016/j.ejcb.2008.08.003
– ident: e_1_2_6_28_1
  doi: 10.1016/j.jnutbio.2013.09.001
– ident: e_1_2_6_22_1
  doi: 10.3389/fphar.2015.00079
– ident: e_1_2_6_30_1
  doi: 10.1038/sj.ijo.0803606
– ident: e_1_2_6_15_1
  doi: 10.1016/j.cmet.2011.10.002
– ident: e_1_2_6_10_1
  doi: 10.1038/ijo.2015.23
– ident: e_1_2_6_18_1
  doi: 10.1016/j.numecd.2010.03.003
– ident: e_1_2_6_9_1
  doi: 10.1139/apnm-2015-0075
– ident: e_1_2_6_13_1
  doi: 10.1016/j.biochi.2012.01.008
– ident: e_1_2_6_6_1
  doi: 10.1016/S0024-3205(99)00410-5
– ident: e_1_2_6_31_1
  doi: 10.1002/oby.20263
– ident: e_1_2_6_4_1
  doi: 10.1111/obr.12318
– ident: e_1_2_6_23_1
  doi: 10.1161/circ.106.25.3143
– ident: e_1_2_6_3_1
  doi: 10.1093/ajcn/55.1.309s
– ident: e_1_2_6_34_1
  doi: 10.2337/diacare.27.10.2488
– volume: 21
  start-page: 893
  ident: e_1_2_6_38_1
  article-title: Why do we need drugs to treat the patient with obesity?
  publication-title: Obesity (Silver Spring)
  doi: 10.1002/oby.20394
– ident: e_1_2_6_26_1
  doi: 10.1111/j.1365-2796.2006.01702.x
– volume: 13
  start-page: 322
  year: 2005
  ident: e_1_2_6_24_1
  article-title: Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary
  publication-title: Cardiol Rev
  doi: 10.1097/01.crd.0000380842.14048.7e
– ident: e_1_2_6_27_1
  doi: 10.1016/j.cell.2012.01.017
– start-page: 1
  year: 2014
  ident: e_1_2_6_17_1
  article-title: Proposed trial: safety and efficacy of resveratrol for the treatment of non‐alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents ‐ rationale and protocol
  publication-title: Biochem Cell Biol
– ident: e_1_2_6_35_1
  doi: 10.1016/j.atherosclerosis.2009.08.020
– volume-title: Anthropometric Standardization Reference Manual
  year: 1988
  ident: e_1_2_6_25_1
– ident: e_1_2_6_20_1
  doi: 10.3389/fphar.2015.00199
– ident: e_1_2_6_12_1
  doi: 10.1017/S0007114511002753
– ident: e_1_2_6_2_1
  doi: 10.1155/2013/136584
– ident: e_1_2_6_5_1
  doi: 10.1016/j.phrs.2011.07.004
– ident: e_1_2_6_33_1
  doi: 10.1016/j.ejim.2012.06.013
SSID ssj0046051
Score 2.3988805
Snippet Objective To evaluate the efficacy of an orlistat‐resveratrol (O‐R) combination in subjects with obesity over a 6‐month period. Methods This study was a...
To evaluate the efficacy of an orlistat-resveratrol (O-R) combination in subjects with obesity over a 6-month period. This study was a double-blind, parallel,...
To evaluate the efficacy of an orlistat-resveratrol (O-R) combination in subjects with obesity over a 6-month period. This study was a double-blind, parallel,...
To evaluate the efficacy of an orlistat-resveratrol (O-R) combination in subjects with obesity over a 6-month period.OBJECTIVETo evaluate the efficacy of an...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1454
SubjectTerms Adult
Aged
Anthropometry
Anti-Obesity Agents - therapeutic use
Body Mass Index
Caloric Restriction
Clinical trials
Compliance
Cytokines
Diet
Double-Blind Method
Drug Therapy, Combination
Energy Intake - drug effects
FDA approval
Female
Glucose
Humans
Lactones - administration & dosage
Lactones - therapeutic use
Leptin - blood
Lipids
Male
Metabolism
Mexico
Middle Aged
Musculoskeletal system
Nutrition research
Obesity
Obesity - blood
Obesity - drug therapy
Placebos
Rodents
Stilbenes - administration & dosage
Stilbenes - therapeutic use
Studies
Treatment Outcome
Triglycerides - blood
Weight control
Weight Loss
Title Efficacy of an orlistat‐resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Foby.21523
https://www.ncbi.nlm.nih.gov/pubmed/27221771
https://www.proquest.com/docview/1807487275
https://www.proquest.com/docview/1800129058
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAviDuFgQziAalyae4Jb13XbUDZEOtQ9xQ5iSOKSjKlTSf66znHdi7TijR4iSLXja2cL-fucwh56yW2cOPIYYEvLGYHwma-ESfMT2Mndi1XBLHM8j12j87sTzNn1um0KwSXq6gfb7aeK_kfqsIY0BVPyf4DZeuHwgDcA33hChSG641oPMb6D9ivHYP5oPcVC9QGVwxM6DUWS8YcdFgXjN8mpfBS-kJ7CxCO6OtYltFPmdAhHbK5bhMgj6uDFEvyX_ONSKqE9gXcyjYfbZVWtxZAVfV0jnnWPeUslK7WpN92NRQbMKTZV475fSXXR4VkqH6f94bwFxm1b6cPHcJ3qCewUzx2kuS9CQ7sWRfK9z3OClmC9huXw8M6Y2TEF-ucfcdGvqqMgljyomkldliKNS84GxXlRu9k9YO3nSCGWyfMVnw7sAbMs2RXXhBrW8Y0s1cHtjWovRbnNmxVzPqaSFElavPodx9bAFuN3KxyBY5PwoOzySScjmfTW-S26bkuttLY__i5Ugkw9myo9Aa1o6rE1cB8Xz_4qmJ0zdq5ajxJ7Wd6n9zTZgsdKgw-IB2RPSR3vujEjEfksoIizVPKM7oNirQFRQpQpAqKFKFI5xmtoEgRilRD8QMd0gaItAEilUB8TM4OxtPREdM9PViMEXqWWCYfcJODpRq5wjF82wcp48WmC6a0cAI7cn0vMmLXEMgtUjMFrpFYTmDwNOEggp6QnSzPxDNCMYKeOKbNE0uAWsojHgnDSkDnBSMkja0ueVe90DDWBe-x78oiVKW6zRDefSjffZe8qadeqCov2ybtVlQJNRNYhgYWk_LBCHC65HX9M7BojLvxTOSlnCPdvY7fJU8VNetVTM80Dc8zYLOSvH9fPjzZO5c3z2-w0Atyt_lMdsnOqijFS9CeV9Ericw_1VzGHg
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+an+orlistat-resveratrol+combination+for+weight+loss+in+subjects+with+obesity%3A+A+randomized+controlled+trial&rft.jtitle=Obesity+%28Silver+Spring%2C+Md.%29&rft.au=Arzola-Paniagua%2C+Mar%C3%ADa+Ang%C3%A9lica&rft.au=Garc%C3%ADa-Salgado+L%C3%B3pez%2C+Enrique+Ra%C3%BAl&rft.au=Calvo-Vargas%2C+Cesar+G&rft.au=Guevara-Cruz%2C+Martha&rft.date=2016-07-01&rft.issn=1930-739X&rft.eissn=1930-739X&rft.volume=24&rft.issue=7&rft.spage=1454&rft_id=info:doi/10.1002%2Foby.21523&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1930-7381&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1930-7381&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1930-7381&client=summon